Diabetes Clinical Trial
Official title:
Comparing Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Subjects With Diabetics- A Randomized, Double-Blind, Three-cycle Crossover Phase I Clinical Trial
The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | July 15, 2024 |
Est. primary completion date | July 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - Subjects had to meet all the following criteria to enrol this study 1. Male or female aged 18-64 years (both inclusive); 2. Body mass index 18.5-35.0 kg/m2 (both inclusive); 3. Diagnosed with type 1 diabetes or type 2 diabetes= 12 months at screening; 4. HbA1c =9.0% by local laboratory at screening; 5. Current treatment with any basal-bolus insulin regimen or continuous subcutaneous insulin infusion(CSII) for = 8 weeks. Patients with type 2 diabetes can also take metformin but require a stable metformin dose for =8 weeks; 6. Current total daily insulin treatment < 1.2 U/kg/day, and total daily bolus insulin treatment = 0.3 U/kg/day and < 0.7 U/kg/day. Exclusion Criteria: - Subjects who meet any of the following criteria will be excluded from this study. 1. The following laboratory or ancillary abnormalities were present from screening until randomization: 1) Poor blood pressure control, defined as systolic blood pressure =160 mmHg or diastolic blood pressure =100 mmHg. 2. Subject has any history or evidence meet the following diseases or conditions: 1. have had severe hypoglycaemia episodes within 6 months before screening as judged by the investigator. 2. Have hospitalization due to diabetic ketoacidosis or hyperglycaemic hyperosmolar state within 6 months prior to screening; 3. Proliferative retinopathy, maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the investigator. 3. Previous and anticipated concomitant treatments: 1. Not able or willing to refrain from any use of herbal products and non-routine vitamins within 14 days or within 5 half-lives (whichever is longer), and routine vitamins within 48 hours prior to trial product administration 2. Within 1 month or have within 5 half-lives (whichever is longer) participated in any trail (defined participate in trail as having had randomized) of using investigational drug or therapy prior to screening. 4. General information: 1. Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent nicotine per day). 2. Previous participation in this study. Participation was defined as randomised. 5. Any other situation judged by investigator that may endanger the safety of the subjects or influence the evaluation of the results. |
Country | Name | City | State |
---|---|---|---|
China | The Second Hospital of Anhui Medical University | Hefei | Anhui |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the serum concentration-time curve of insulin aspart | From 0 to 30 mins after trial product administration | ||
Secondary | Area under the serum concentration-time curve of insulin aspart | From 0 to 6 hours after trial product administration | ||
Secondary | Plasma glucose concentration | From 0 to 6 hours after start of a standardised meal | ||
Secondary | Number of subjects with adverse events and severity of adverse events | From first dose to the last visit, approximately 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |